文献速递甲状腺核医学核素与放射性配体治疗

Marine-Lenhart综合征:核医学显像为何仍是诊断与治疗的关键

Marine-Lenhart syndrome: why nuclear medicine imaging remains essential for diagnosis and treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-23

本综述分析近三十年的病例报告与病例系列,聚焦Marine-Lenhart综合征(Graves病合并自主功能性甲状腺结节)的临床表现、诊断方法、患病率、机制与治疗结局。该综合征约占Graves病患者的0.8-4.3%,自主结节在初始扫描常呈「冷结节」并在治疗后显现「揭面效应」,功能显像对诊断与指导放射性碘治疗不可或缺。

要点

  • Marine-Lenhart综合征约占Graves病的0.8-4.3%,诊断标准与显像方法影响患病率。
  • 自主功能性结节可被抑制而在初始扫描呈「冷结节」,治疗后出现「揭面效应」。
  • 该综合征放射性碘治疗需更高活度,且可能需要再次消融。

核心结论

  • 核医学功能显像对Marine-Lenhart综合征的诊断与治疗规划至关重要,可识别自主功能性结节、指导放射性碘治疗并避免治疗失败。

研究设计与样本

  • 综述近三十年发表的病例报告与病例系列,分析临床表现、诊断方法、患病率、疾病机制与治疗结局。

主要发现

  • 该综合征约占Graves病患者的0.8-4.3%,比率随诊断标准与显像方法而异。
  • 自主功能性结节常被抑制而在初始扫描呈「冷结节」,仅在治疗后变得可见,即「揭面效应」。
  • 99mTc-高锝酸盐或123I甲状腺显像提供结构成像无法显示的功能信息。
  • 含冷结节的3型Marine-Lenhart综合征需用超声并在适当时行细针穿刺仔细评估癌症风险。

关键数值与推荐

  • 推荐所有甲状腺功能亢进合并甲状腺结节的患者在开始治疗前行常规甲状腺显像。
  • Marine-Lenhart综合征的放射性碘治疗需要比标准Graves病更高的活度,因结节可能逃逸辐射损伤,且患者可能需要再次放射性碘消融。

临床怎么用

  • 对甲亢合并甲状腺结节患者,治疗前应行甲状腺闪烁显像以识别自主功能性结节并指导放射性碘活度选择。
  • 对含冷结节者,应结合超声并在适当时行细针穿刺评估癌症风险。
  • 放射性碘治疗后需考虑结节逃逸辐射损伤及再次消融的可能。

局限性

  • 本文为病例报告与病例系列的综述,患病率等数据受诊断标准与显像方法差异影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This review examines Marine-Lenhart syndrome (MLS), an uncommon thyroid disorder that combines Graves' disease with autonomously functioning thyroid nodules (AFTNs) and demonstrates why nuclear medicine imaging is essential for accurate diagnosis and treatment planning. METHODS: We reviewed case reports and case series published over the past three decades and analyzed clinical presentation, diagnostic approaches, prevalence rates, disease mechanisms, and treatment outcomes of MLS. RESULTS: This relatively rare syndrome occurs in approximately 0.8-4.3% of patients with Graves' disease, though rates vary depending on the diagnostic criteria and imaging methods used. It presents a diagnostic challenge because AFTNs often remain suppressed and appear "cold" on initial scans, only becoming visible after treatment - the characteristic "unmasking effect". Thyroid scintigraphy with either 99mTc-pertechnetate or 123I provides functional information that structural imaging cannot show. Treatment differs from standard Graves' disease management as MLS requires higher radioiodine activities because nodules may escape radiation damage, and patients may need radioiodine re-ablation. Type 3 MLS, which includes cold nodules, requires careful cancer risk evaluation with ultrasound and fine-needle aspiration when appropriate. CONCLUSION: Nuclear medicine imaging is crucial for MLS diagnosis and treatment planning. Functional imaging identifies AFTNs, guides appropriate radioiodine treatment, and prevents treatment failure. Routine thyroid scintigraphy is recommended in all patients with hyperthyroidism and thyroid nodules before starting therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Petranović Ovčariček P, Ruggeri RM, Campennì A, et al. Marine-Lenhart syndrome: why nuclear medicine imaging remains essential for diagnosis and treatment. Eur J Nucl Med Mol Imaging. 2026. PMID: 41571841. doi:10.1007/s00259-025-07751-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。